Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
IFM Quattro
AddedFeb 18, 2024
UpdatedJun 18, 2026
IFM Quattro

IFM Quattro

Seed

IFM Quattro: A Boston-based biotech software company, founded in 2019 by H. Martin Seidel.

HQ
Boston, MA, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

IFM Quattro, a Boston-based biotech software company, was founded in 2019 by H. Martin Seidel. The company's core mission is to improve the lives of patients with inflammation-driven diseases and cancer by developing transformative medicines that precisely target the innate immune system. IFM Quattro focuses on creating first-in-class medicines that regulate immune responses, leveraging advanced biotechnology and software solutions to achieve their goals.

Notable affiliated individuals include founder H. Martin Seidel, who has a significant background in biotechnology. The company has made key achievements in advancing its research pipeline, contributing to the development of innovative treatments for complex diseases. IFM Quattro's impact lies in its potential to revolutionize the treatment of inflammation-driven diseases and cancer, positioning itself as a leader in the biotech software sector.

IFM Quattro - Similar Companies

Inmagene Biopharmaceuticals logo

Inmagene Biopharmaceuticals

inmagenebio.com

Imidomics logo

Imidomics

imidomics.com

HI-Bio logo

HI-Bio

hibio.com

Seismic Therapeutic logo

Seismic Therapeutic

Immuneering logo

Immuneering

immuneering.com

IM Therapeutics logo

IM Therapeutics

imtherapeutics.com

HBM Genomics logo

HBM Genomics

BostonGene logo

BostonGene

bostongene.com

Imvaq Therapeutics logo

Imvaq Therapeutics

Intellimedix logo

Intellimedix

Qrativ logo

Qrativ

qrativ.bio

Endpoint Health logo

Endpoint Health

Innox logo

Innox

innoxpharma.com

Marlinspike Therapeutics logo

Marlinspike Therapeutics

IntelligentMDx logo

IntelligentMDx

IFM Quattro - Quick Facts

Who are IFM Quattro's competitors?

Companies similar to IFM Quattro include Inmagene Biopharmaceuticals, Imidomics, HI-Bio and Seismic Therapeutic.

When was IFM Quattro founded?

IFM Quattro was founded in 2019.

Where is IFM Quattro's headquarters located?

IFM Quattro's headquarters is located in Boston, MA, US.

When was IFM Quattro's last funding round?

IFM Quattro's most recent funding round was for $350k (USD) in December 2019.

How much has IFM Quattro raised to-date?

As of Dec 17, 2019, IFM Quattro has raised a total of $350k (USD).

How many employees does IFM Quattro have?

IFM Quattro has 30 employees as of Feb 5, 2024.

IFM Quattro - Classification

Ownership
  • Private
Technology
  • Biotech
  • Software
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Biotech Software
Tags
  • SaaS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software